Neurology Central

Phase II/III trials of umibecestat to discontinue for Alzheimer’s disease: industry news round-up

In this week’s industry news round-up we cover the latest headlines on trial discontinuations in both the Alzheimer’s and ALS fields, alongside a drug discovery shift from the amyloid approach in Alzheimer’s disease. Find out more about our selection of the headlines below:

ADDF clinical trial report demonstrates notable shift from amyloid approach

A new clinical trial report, which has been released by the Alzheimer’s Drug Discovery Foundation (ADDF), has indicated that researchers are developing drugs for various targets associated with aging biology that move beyond traditional approaches with amyloid and tau.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.